Dermata Therapeutics (NASDAQ: DRMAW) resolves Nasdaq bid-price deficiency

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company had previously been notified on May 14, 2025 that its common stock failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days and that, because it had implemented a reverse stock split within the prior year, its securities were subject to potential delisting from the Nasdaq Capital Market.

After Dermata requested a hearing and was granted an exception until August 14, 2025 to regain compliance, Nasdaq staff notified the company on August 22, 2025 that it once again satisfies the minimum bid price requirement and that the matter is closed. This removes the previously disclosed risk that Dermata’s securities could be suspended or delisted from Nasdaq based on the minimum bid price issue.

Positive

• Nasdaq listing compliance restored: Nasdaq staff confirmed on August 22, 2025 that Dermata again meets the $1.00 minimum bid price requirement, closing the prior delisting matter.

Negative

• None.

Insights

Equity Market Listing & Compliance Analyst

Dermata has resolved a Nasdaq bid-price deficiency, removing an immediate delisting risk.

The company discloses it was previously below Nasdaq’s $1.00 minimum bid price requirement for 30 consecutive business days, which triggered a deficiency notice and potential delisting. Because a reverse stock split had occurred within the prior year, Dermata’s securities were at heightened risk of suspension from the Nasdaq Capital Market.

Dermata requested a hearing and received an exception period through August 14, 2025 to regain compliance. On August 22, 2025, Nasdaq staff confirmed the company now meets the minimum bid price requirement and that the matter is closed. This outcome preserves the Nasdaq listing and removes the specific compliance overhang tied to the minimum bid price rule; future listing status will continue to depend on ongoing compliance with Nasdaq’s standards.

false 0001853816 0001853816 2025-08-22 2025-08-22 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2025-08-22 2025-08-22 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2025-08-22 2025-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2025

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

3525 Del Mar Heights Rd., #322, San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 800-2543

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01. Other Events.

As previously reported, on May 14, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation of a reverse stock split within the prior one-year period, the Company’s securities were subject to delisting from the Nasdaq Capital Market and would be suspended at the opening of business on May 23, 2025. The Company timely requested a hearing before the Panel, which request stayed any further suspension or delisting action by Nasdaq, pending the ultimate conclusion of the hearing process.

On July 2, 2025, the Panel notified the Company that it had granted the Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement.

On August 22, 2025, the Company received a letter from the Staff indicating that the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: August 25, 2025	By:	/s/ Gerald T. Proehl
	Name:	Gerald T. Proehl
	Title:	Chief Executive Officer

FAQ

What did Dermata Therapeutics, Inc. (DRMAW) announce in this 8-K?

Dermata Therapeutics, Inc. reported that Nasdaq staff notified the company on August 22, 2025 that it has regained compliance with the minimum bid price requirement for continued listing, and that the matter is now closed.

Why was Dermata Therapeutics previously at risk of delisting from Nasdaq?

Nasdaq’s Listing Qualifications Department informed Dermata on May 14, 2025 that its common stock’s closing bid price had been below $1.00 per share for 30 consecutive business days, and, because the company had implemented a reverse stock split within the prior year, its securities were subject to potential suspension and delisting from the Nasdaq Capital Market.

What exception did Nasdaq grant Dermata Therapeutics regarding the bid price rule?

A Nasdaq hearings panel notified Dermata on July 2, 2025 that it granted the company an exception until August 14, 2025 to demonstrate compliance with the $1.00 minimum bid price requirement for its common stock.

When did Dermata Therapeutics regain compliance with Nasdaq’s minimum bid price requirement?

Dermata received a letter from Nasdaq staff on August 22, 2025 stating that the company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Which Dermata securities are listed on The Nasdaq Capital Market?

Dermata lists its common stock, par value $0.0001 per share, under the symbol DRMA, and warrants exercisable for one share of common stock under the symbol DRMAW on The Nasdaq Capital Market.

What does the closing of the Nasdaq bid price matter mean for Dermata Therapeutics?

With Nasdaq staff indicating that Dermata has regained compliance and that the matter is closed, the previously disclosed bid price deficiency and related delisting and suspension risk tied to that issue have been resolved, subject to the company’s continued adherence to Nasdaq listing standards.